Literature DB >> 23942767

Impact of cardiac involvement on the risk of mortality among patients with systemic sclerosis: a 5-year follow-up of a single-center cohort.

Gyöngyvér Költő1, Réka Faludi, Dániel Aradi, Barbara Bartos, Gábor Kumánovics, Tünde Minier, László Czirják, András Komócsi.   

Abstract

Cardiac involvement is among the leading causes of mortality in patients with systemic sclerosis (SSc). Previously, we demonstrated in a single-center, cross-sectional study the frequent coexistence of different forms of cardiac involvement in systemic sclerosis including pulmonary arterial hypertension (PAH), coronary artery disease (CAD), and microvascular dysfunction (MVD). The aim of the present study was to investigate the prognostic significance of cardiac involvement. One hundred twenty patients with SSc were enrolled. All cases underwent a non-invasive cardiovascular protocol. In 30 patients with suspected cardiac involvement, right heart catheterization and intra-coronary pressure-wire-supplemented coronary angiography were performed. Clinical follow-up was 5 years. Patients with CAD at the baseline showed a trend for higher cardiovascular mortality while in patients with MVD this difference was significant (26.7 % versus 9.5 %, p = 0.077 and 30 % versus 10.1 %, p < 0.05, respectively). Cardiovascular mortality of PAH cases was higher but, however, did not reach statistical significance 21.4 % versus 10.4 %, p = 0.261. Cardiovascular event-free survival was significantly lower among patients with combinations of two or three disorders (p < 0.05). Multivariate analysis of organ involvements and comorbidities showed that the diffuse cutaneous subset, the presence of kidney involvement, the velocity of the tricuspid regurgitation, as well as diabetes mellitus were independent predictors of overall mortality. MVD and CAD alone or in combination with PAH significantly affected the 5-year cardiovascular mortality. These findings highlight the prognostic importance of coronary disease in patients with SSc [ www.clinicaltrials.gov (Reg. Nr.: NCT00843102)].

Entities:  

Mesh:

Year:  2013        PMID: 23942767     DOI: 10.1007/s10067-013-2358-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

1.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

Authors:  Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert
Journal:  Arthritis Rheum       Date:  2005-12

Review 2.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.

Authors:  Marc Humbert; Azzedine Yaici; Pascal de Groote; David Montani; Olivier Sitbon; David Launay; Virginie Gressin; Loïc Guillevin; Pierre Clerson; Gérald Simonneau; Eric Hachulla
Journal:  Arthritis Rheum       Date:  2011-11

Review 4.  Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies.

Authors:  Christophe Meune; Olivier Vignaux; André Kahan; Yannick Allanore
Journal:  Arch Cardiovasc Dis       Date:  2009-11-28       Impact factor: 2.340

5.  Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study.

Authors:  Yannick Allanore; Christophe Meune; Olivier Vignaux; Simon Weber; Paul Legmann; Andre Kahan
Journal:  J Rheumatol       Date:  2006-10-15       Impact factor: 4.666

6.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Michael McGoon; David Gutterman; Virginia Steen; Robin Barst; Douglas C McCrory; Terry A Fortin; James E Loyd
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

Review 7.  Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.

Authors:  Christopher J Ryerson; Shalini Nayar; John R Swiston; Don D Sin
Journal:  Respir Res       Date:  2010-01-29

8.  Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis.

Authors:  Y Allanore; C Meune; M C Vonk; P Airo; E Hachulla; P Caramaschi; G Riemekasten; F Cozzi; L Beretta; C T Derk; A Komócsi; D Farge; A Balbir; V Riccieri; O Distler; A Chialà; N Del Papa; K Pasalic Simic; M Ghio; B Stamenkovic; S Rednic; N Host; R Pellerito; E Zegers; A Kahan; U A Walker; M Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

9.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

10.  Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study.

Authors:  Eric Hachulla; Patrick Carpentier; Virginie Gressin; Elisabeth Diot; Yannick Allanore; Jean Sibilia; David Launay; Luc Mouthon; Patrick Jego; Jean Cabane; Pascal de Groote; Amélie Chabrol; Isabelle Lazareth; Loïc Guillevin; Pierre Clerson; Marc Humbert
Journal:  Rheumatology (Oxford)       Date:  2009-01-27       Impact factor: 7.580

View more
  4 in total

Review 1.  Cardiac manifestations in systemic sclerosis.

Authors:  Sevdalina Lambova
Journal:  World J Cardiol       Date:  2014-09-26

2.  Contractile reserve in systemic sclerosis patients as a major predictor of global cardiac impairment and exercise tolerance.

Authors:  Christian Cadeddu; Martino Deidda; Giuseppina Giau; Marzia Lilliu; Fabio Cadeddu; Giulio Binaghi; Mario Nicola Mura; Michela Farci; Stefano Del Giacco; Paolo Emilio Manconi; Giuseppe Mercuro
Journal:  Int J Cardiovasc Imaging       Date:  2014-12-30       Impact factor: 2.357

3.  Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature.

Authors:  M R Pokeerbux; J Giovannelli; L Dauchet; L Mouthon; C Agard; J C Lega; Y Allanore; P Jego; B Bienvenu; S Berthier; A Mekinian; E Hachulla; D Launay
Journal:  Arthritis Res Ther       Date:  2019-04-03       Impact factor: 5.156

4.  Galectin-3 and sST2: associations to the echocardiographic markers of the myocardial mechanics in systemic sclerosis - a pilot study.

Authors:  Vivien Vértes; Adél Porpáczy; Ágnes Nógrádi; Margit Tőkés-Füzesi; Máté Hajdu; László Czirják; András Komócsi; Réka Faludi
Journal:  Cardiovasc Ultrasound       Date:  2022-01-18       Impact factor: 2.062

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.